Natixis Advisors, L.P. Crinetics Pharmaceuticals, Inc. Transaction History
Natixis Advisors, L.P.
- $63 Billion
- Q2 2025
A detailed history of Natixis Advisors, L.P. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 47,115 shares of CRNX stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,115
Previous 46,509
1.3%
Holding current value
$2 Million
Previous $1.56 Million
13.14%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CRNX
# of Institutions
236Shares Held
90MCall Options Held
59.7KPut Options Held
14.8K-
Vanguard Group Inc Valley Forge, PA9.26MShares$393 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.4MShares$272 Million1.78% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$265 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA5.81MShares$247 Million0.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.59MShares$238 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.28B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...